시장보고서
상품코드
1485241

BNP 및 NT-proBNP 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 검사장소별, 용도별, 지역별, 경쟁별(2019-2029년)

BNP And NTproBNP Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, NT-proBNP, By Location of Testing, By Application, By Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 185 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 BNP·NT-proBNP 시장 규모는 2023년에 18억 4,056만 달러로 평가되며, 2029년까지의 CAGR은 7.25%로, 예측 기간 중 꾸준한 성장을 예측하고 있습니다.

BNP(뇌성 나트륨이뇨펩티드)와 NT-proBNP(N-말단 프로 B형 나트륨이뇨펩티드)는 의료와 진단 분야, 특히 심장병학과 심장 관련 질환에 사용되는 바이오마커입니다. 이 마커는 심장질환의 평가와 관리에서 중요한 역할을 담당하고 있으며, 세계의 의료 시장에 필수적인 요소가 되고 있습니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 18억 4,056만 달러
시장 규모 : 2029년 27억 8,544만 달러
CAGR : 2024-2029년 7.25%
급성장 부문 POC(Point of Care) 검사
최대 시장 북미

BNP·NT-proBNP 시장은 광범위한 진단·의료 산업의 중요한 부문입니다. 이 시장에는 이 이러한 바이오마커의 측정, 분석 및 활용과 관련된 다양한 제품과 서비스가 포함됩니다. 이 시장은 몇 가지 주요 컴포넌트로 나눌 수 있는데, BNP·NT-proBNP 시장은 전 세계 심혈관 질환의 유병률 증가로 인해 수년 동안 꾸준한 성장세를 보이고 있습니다. 인구 고령화, 좌식 생활습관, 비만 및 당뇨병과 같은 위험 요인이 증가함에 따라 심장 관련 문제를 정확하고 조기에 발견해야 할 필요성이 증가하고 있습니다. 시장 경쟁은 치열하며, 여러 세계 및 지역 기업이 존재합니다. 이 시장에 진출한 주요 기업으로는 Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific 등이 있습니다. 이들 기업은 분석법, 기기, 현장진단기기 등 다양한 BNP/NT-proBNP 검사 솔루션을 제공합니다. 이 분야에서의 경쟁은 제품 혁신, 가격 책정, 의료 서비스 프로바이더와의 강력한 파트너십을 구축하는 능력에 따라 좌우됩니다.

BNP?NT-proBNP 마커는 주로 심장 관련 질환의 진단 및 모니터링에 사용됩니다. 심부전 평가, 심부전과 다른 호흡기 질환의 감별, 환자 예후 예측 및 치료 방침을 결정하는 데 도움이 됩니다. 맞춤형 의료와 표적치료에 대한 수요가 증가함에 따라 이러한 바이오마커는 심장병 환자의 치료 전략을 조정하는 데 더욱 중요해질 것입니다. 이 시장은 기술 발전과 비침습적이고 신속한 진단 방법에 대한 관심 증가로 인해 지속적으로 발전하고 있습니다. 여기에는 고감도 분석법 개발, 데이터 분석에 인공지능과 머신러닝의 통합, 더 빠르고 간편한 검사를 가능하게 하는 휴대용 현장 검사 기기의 출현 등이 포함됩니다. 원격의료와 원격 모니터링의 도입은 BNP·NT-proBNP 마커의 활용에 새로운 기회를 가져왔으며, BNP·NT-proBNP 시장은 특히 신흥 국가 시장에서 엄격한 규제 감독을 받고 있습니다. 예를 들어 미국 식품의약국(FDA)은 이러한 진단 약품의 승인과 판매를 엄격하게 모니터링하고 있습니다. 규제 요건을 준수하고 품질 기준을 준수하는 것은 이 시장에서 사업을 운영하는 기업에게 필수적입니다.

시장에는 많은 성장 기회가 있는 반면, 비용 제약과 상환 문제와 같은 도전과제도 있습니다. 바이오마커의 도입은 의료시스템의 예산 제약으로 인해 제한되어 고급 진단 검사에 대한 접근이 제한될 수 있습니다. 그러나 BNP/NT-proBNP 검사의 임상적 유용성에 대한 인식이 높아지고, 임상 가이드라인에 포함된다면 큰 성장 가능성을 기대할 수 있습니다. 결론적으로, BNP/NT-proBNP 시장은 심장병 발병률 증가와 정확하고 시기적절한 진단 솔루션에 대한 수요에 힘입어 의료 및 진단 산업의 중요한 컴포넌트로 자리 잡았으며, BNP/NT-proBNP 시장은 다양한 제품, 서비스 및 기술을 포괄하고 있으며, 경쟁 구도는 세계 대기업이 주도하고 있습니다. 경쟁 구도는 세계 대기업이 주도하고 있습니다. 기술 발전이 계속되고 의료 및 시스템이 비용 효율적인 솔루션을 추구함에 따라 BNP/NT-proBNP 시장은 더욱 성장하고 혁신할 준비가 되어 있으며, 궁극적으로 순환기 분야의 환자 치료와 결과를 개선하는 데 기여할 것입니다.

주요 시장 촉진요인

심혈관질환의 증가

맞춤형 의료의 동향

주요 시장이 해결해야 할 과제

의료 시스템에서의 비용 제약

대체 진단법과의 경쟁

검사 결과 격차

규제 준수와 품질 기준

주요 시장 동향

원격의료와 원격 모니터링

고감도 어세이의 개발

AI와 기계학습의 통합

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 BNP·NT-proBNP 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율·예측
    • 유형별(BNP(뇌성 나트륨이뇨펩티드), NT-proBNP(N말단 프로 B형 나트륨이뇨펩티드))
    • 검사장소별(POC(Point of Care) 검사, 임상 검사)
    • 용도별(심근경색, 울혈성심부전, 급성 관상동맥 증후군(ACS), 기타)
    • 지역별
    • 기업별(2023년)
  • 시장 맵
    • 유형별
    • 검사장소별
    • 용도별
    • 지역별

제5장 아시아태평양의 BNP·NT-proBNP 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율·예측
    • 유형별
    • 검사장소별
    • 용도별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제6장 유럽의 BNP·NT-proBNP 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율·예측
    • 유형별
    • 검사장소별
    • 용도별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제7장 북미의 BNP·NT-proBNP 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율·예측
    • 유형별
    • 검사장소별
    • 용도별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 남미의 BNP·NT-proBNP 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율·예측
    • 유형별
    • 검사장소별
    • 용도별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제9장 중동 및 아프리카의 BNP·NT-proBNP 시장 전망

  • 시장 규모·예측
    • 금액별
  • 시장 점유율·예측
    • 유형별
    • 검사장소별
    • 용도별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트

제10장 시장 역학

  • 촉진요인
  • 과제

제11장 시장 동향과 발전

  • 최근 동향
  • 제품 발매
  • 합병과 인수

제12장 세계의 BNP·NT-proBNP 시장 : SWOT 분석

제13장 Porter의 산업 분석

  • 업계내의 경쟁
  • 신규 참여의 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • Specim, Spectral Imaging Ltd
  • Gentian Diagnostics ASA
  • Siemens AG
  • PerkinElmer Inc
  • Biomerieux SA
  • Quidel Corporation
  • Bio-Rad Laboratories, Inc.
  • F. Hoffman-La Roche Ltd
  • BHR Pharmaceuticals Ltd.
  • Xiamen Biotime Biotechnology Co., Ltd.

제15장 전략적 제안

제16장 조사회사 소개·면책사항

KSA 24.06.05

Global BNP And NT-proBNP Market was valued at USD 1840.56 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 7.25% through 2029. BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) are biomarkers used in the field of healthcare and diagnostics, particularly in cardiology and heart-related conditions. These markers play a crucial role in the assessment and management of heart diseases, making them an essential component of the global healthcare market.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 1840.56 Million
Market Size 2029USD 2785.44 Million
CAGR 2024-20297.25%
Fastest Growing SegmentPoint Of Care Testing
Largest MarketNorth America

The BNP and NT-proBNP market is a vital segment of the broader diagnostic and healthcare industry. It encompasses a wide range of products and services related to the measurement, analysis, and utilization of these biomarkers. This market's description can be broken down into several key components. The BNP and NT-proBNP market has been experiencing steady growth over the years due to the increasing prevalence of cardiovascular diseases worldwide. With the aging population, sedentary lifestyles, and the rise in risk factors such as obesity and diabetes, there is a growing need for accurate and early detection of heart-related issues. The market is highly competitive, with several global and regional players. Major companies involved in this market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific, among others. These companies offer a variety of BNP and NT-proBNP testing solutions, including assays, instruments, and point-of-care devices. The competition in this sector is driven by product innovation, pricing, and the ability to establish strong partnerships with healthcare providers.

BNP and NT-proBNP markers are primarily used in diagnosing and monitoring heart-related conditions. They are instrumental in assessing heart failure, distinguishing between heart failure and other respiratory disorders, predicting patient outcomes, and guiding treatment decisions. As the demand for personalized medicine and targeted therapies grows, these biomarkers become even more critical in tailoring treatment strategies for heart patients. The market is continually evolving, driven by technological advancements and a growing focus on non-invasive and rapid diagnostic methods. This includes the development of high-sensitivity assays, integration of artificial intelligence and machine learning in data analysis, and the emergence of portable point-of-care devices that enable quicker and more convenient testing. The adoption of telemedicine and remote monitoring has opened new opportunities for the utilization of BNP and NT-proBNP markers. The BNP and NT-proBNP market is subject to stringent regulatory oversight, particularly in developed regions. In the United States, for instance, the Food and Drug Administration (FDA) closely monitors the approval and marketing of these diagnostic products. Compliance with regulatory requirements and adherence to quality standards are essential for companies operating in this market.

While the market presents numerous growth opportunities, it also faces challenges, such as cost constraints and reimbursement issues. The adoption of these biomarkers can be hindered by budget constraints in healthcare systems, which may limit access to advanced diagnostic tests. However, the increasing awareness of the clinical benefits of BNP and NT-proBNP testing and the incorporation of these markers into clinical guidelines provide significant growth prospects. In conclusion, the BNP and NT-proBNP market is a crucial component of the healthcare and diagnostics industry, driven by the rising incidence of heart diseases and the demand for accurate and timely diagnostic solutions. It encompasses a wide range of products, services, and technologies, with a competitive landscape dominated by leading global companies. As technology continues to advance and healthcare systems seek cost-effective solutions, the BNP and NT-proBNP market is poised for further growth and innovation, ultimately contributing to improved patient care and outcomes in the field of cardiology.

Key Market Drivers

Increasing cardiovascular diseases

The increasing prevalence of cardiovascular diseases is a significant driver of the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. Cardiovascular diseases, including heart failure, coronary artery disease, and hypertension, have reached epidemic proportions globally. This surge in heart-related conditions is attributed to several factors, which in turn fuel the demand for BNP and NT-proBNP testing. Firstly, the aging population is a major contributor to the rise in cardiovascular diseases.

As the world's population continues to age, there is a higher incidence of heart-related conditions, particularly heart failure, which becomes more prevalent with advancing age. This demographic shift places an increasing burden on healthcare systems, making early and accurate diagnosis of heart diseases crucial. Lifestyle changes and risk factors such as obesity, sedentary lifestyles, and unhealthy dietary habits have become more widespread. These factors significantly contribute to the development of heart diseases, making proactive screening and monitoring of cardiac health essential. The growing awareness of the importance of cardiovascular health has led to increased screening and early detection efforts. As patients and healthcare providers recognize the need for timely diagnosis, BNP and NT-proBNP testing become critical tools for identifying heart conditions in their early stages. This awareness has led to a surge in the demand for diagnostic testing, further driving market growth.

The complexity of cardiovascular diseases and the need for precision medicine have led to a more personalized approach to patient care. BNP and NT-proBNP markers play a pivotal role in tailoring treatment strategies, guiding therapy decisions, and assessing prognosis. Their ability to provide accurate insights into the patient's cardiac status positions them as indispensable tools in the management of heart diseases. In recent years, the healthcare landscape has been transformed by the adoption of telemedicine and remote patient monitoring. These technologies enable patients to receive cardiac assessments and monitoring without frequent in-person visits, making BNP and NT-proBNP testing even more relevant. Healthcare providers can remotely track patients' cardiac health, ensuring early intervention when necessary. Regulatory bodies and clinical guidelines increasingly endorse the use of BNP and NT-proBNP markers in heart disease management. This official support enhances the credibility and adoption of these biomarkers in clinical practice, encouraging healthcare providers to incorporate them into their diagnostic and treatment protocols.

Personalized medicine trends

The BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market is experiencing a significant boost due to the increasing adoption of personalized medicine trends. Personalized medicine, also known as precision medicine, is a healthcare approach that tailors medical care to the individual characteristics of each patient. In the context of heart-related conditions, this approach relies on precise diagnostic tools such as BNP and NT-proBNP markers to offer more targeted and effective treatments.

BNP and NT-proBNP play a vital role in the era of personalized medicine for several reasons: Personalized medicine seeks to identify an individual's unique risk factors and genetic predispositions. BNP and NT-proBNP testing provide essential information on a patient's cardiac health status. Elevated levels of these biomarkers can signify a higher risk of cardiovascular events, allowing healthcare providers to implement preventive strategies for high-risk individuals. In the context of heart failure, distinguishing it from other respiratory or cardiac conditions is crucial. BNP and NT-proBNP levels are highly specific to heart failure. Accurate diagnosis is the first step in personalized medicine, enabling the selection of the most suitable treatment options based on the patient's condition.

Once a patient's heart condition is accurately diagnosed, personalized medicine considers factors such as the patient's age, genetic profile, comorbidities, and lifestyle. BNP and NT-proBNP markers help guide treatment decisions. Physicians can choose medications, interventions, and therapies that are most likely to be effective, minimizing adverse effects and optimizing outcomes. The ongoing monitoring of a patient's cardiac health is integral to personalized medicine. BNP and NT-proBNP levels are monitored to assess the patient's response to treatment. If these biomarkers remain elevated or increase, healthcare providers can promptly adjust the treatment plan to better suit the patient's evolving needs.

Personalized medicine aims to predict a patient's likely response to treatment and their long-term prognosis. BNP and NT-proBNP levels serve as valuable prognostic tools, helping healthcare providers anticipate the patient's future health trajectory. This enables timely interventions and adjustments to improve the patient's quality of life and overall outcomes. As personalized medicine continues to gain prominence in healthcare, the demand for precise and individualized diagnostic tools like BNP and NT-proBNP is set to increase. Healthcare providers are increasingly incorporating these markers into their diagnostic and treatment protocols, allowing them to offer more effective and patient-centered care.

Key Market Challenges

Cost constraints in healthcare systems

Cost constraints in healthcare systems are driving the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market by emphasizing the need for cost-effective diagnostics. Healthcare providers and payers seek efficient ways to diagnose and manage cardiovascular diseases, given the economic pressures on the healthcare system. BNP and NT-proBNP testing, while essential for accurate cardiac assessments, are becoming more accessible and affordable. Market players are focusing on developing economical diagnostic solutions, including point-of-care devices, to address these constraints. This cost-conscious approach ensures that essential cardiac diagnostics are more widely available, contributing to the market's growth and relevance in a healthcare landscape driven by financial sustainability.

Competition from alternative diagnostic methods

Competition from alternative diagnostic methods is a driving force behind the growth of the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. As the healthcare industry witnesses continuous innovation, alternative cardiac diagnostic techniques and markers emerge. In response, companies in the BNP and NT-proBNP market strive to maintain their competitive edge by enhancing their assays, improving accuracy, and streamlining testing processes. This competition spurs innovation, fosters the development of more efficient and cost-effective diagnostic solutions, and ultimately benefits patients by ensuring a broader array of diagnostic tools and options for cardiac assessment. It encourages continuous advancement within the BNP and NT-proBNP market to stay relevant and valuable in a dynamic healthcare landscape.

Variability in test results

Variability in test results within the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market serves as a catalyst for growth. This challenge highlights the need for more precise and standardized testing methodologies. To address this, companies invest in research and development to enhance the accuracy and consistency of their BNP and NT-proBNP assays. The demand for more reliable tests, with reduced variability, drives innovation, leading to the development of high-sensitivity assays and advanced diagnostic technologies. Healthcare providers and clinicians seek dependable results to make critical treatment decisions, and as the market responds to this demand, it experiences sustained growth and expansion.

Regulatory compliance and quality standards

Regulatory compliance and adherence to quality standards play a crucial role in driving the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. Stricter regulations ensure that diagnostic tests meet rigorous safety and efficacy requirements, instilling confidence in healthcare providers and patients. The stringent oversight fosters innovation, as companies invest in research and development to meet these standards. Moreover, adherence to quality standards enhances the reliability and accuracy of BNP and NT-proBNP tests, making them indispensable tools in clinical practice. This regulatory support not only encourages market growth but also bolsters the credibility and trust associated with these cardiac biomarkers.

Key Market Trends

Telemedicine and remote monitoring

Telemedicine and remote monitoring have emerged as pivotal trends in the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. These technologies enable healthcare providers to remotely assess and monitor patients' cardiac health, reducing the need for frequent in-person visits. BNP and NT-proBNP testing, with their ability to provide valuable cardiac insights, are integrated into these remote monitoring systems. As telemedicine gains traction, the demand for accurate and real-time cardiac diagnostics becomes more critical. BNP and NT-proBNP testing facilitate continuous patient monitoring and timely intervention, making them indispensable components in the shift towards more patient-centric and efficient healthcare delivery. This trend further drives the growth of the BNP and NT-proBNP market.

High-sensitivity assays development

High-sensitivity assays development is a notable trend in the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. These assays offer enhanced precision and lower detection limits, allowing for the measurement of even trace amounts of these biomarkers. High-sensitivity assays are particularly valuable in early disease detection and risk stratification, as they can identify cardiac issues at their nascent stages. This trend reflects the industry's commitment to improving diagnostic accuracy and clinical outcomes, reinforcing the importance of BNP and NT-proBNP markers in cardiology. The development of high-sensitivity assays further solidifies the position of these biomarkers in the forefront of cardiac diagnostics and patient care.

Integration of AI and machine learning

The integration of AI (Artificial Intelligence) and machine learning is a compelling trend in the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. These advanced technologies have the potential to revolutionize cardiac diagnostics by enhancing data analysis and interpretation. AI-driven algorithms can rapidly process vast amounts of patient data, including BNP and NT-proBNP levels, to assist healthcare providers in making more accurate diagnoses and treatment decisions. Machine learning models can predict patient outcomes and identify patterns that might be missed through traditional methods. This trend not only improves the efficiency and accuracy of testing but also positions BNP and NT-proBNP markers at the forefront of cutting-edge, data-driven healthcare solutions.

Segmental Insights

Location of Testing Insights

Based on the location of testing, Point of care testing has emerged as the fastest growing segment in the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market, revolutionizing cardiac diagnostics. These portable, rapid, and user-friendly POCT devices enable healthcare professionals to conduct BNP and NT-proBNP testing at the patient's bedside or in primary care settings, ensuring quicker results and immediate clinical decision-making. POCT is especially valuable in emergency departments and critical care situations, expediting the identification and management of cardiac conditions. This trend aligns with the growing emphasis on timely and convenient healthcare solutions, making BNP and NT-proBNP testing more accessible, reducing diagnostic turnaround times, and enhancing patient care in various clinical settings.

Application Insights

Based on application, Myocardial Infarction, commonly known as a heart attack, has emerged as the dominating segment of the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market. These cardiac biomarkers play a pivotal role in the diagnosis and management of MI. Elevated BNP and NT-proBNP levels are indicative of cardiac stress, making them crucial in the early identification of MI. Rapid and accurate MI diagnosis is essential for timely interventions, reducing the risk of life-threatening complications. With the global burden of MI increasing, the demand for these biomarkers as reliable diagnostic tools in emergency settings continues to rise, cementing their significance in the field of cardiology.

Regional Insights

North America has dominated the BNP (Brain Natriuretic Peptide) and NT-proBNP (N-Terminal pro-Brain Natriuretic Peptide) market in 2023 for several reasons. The region has a well-established and technologically advanced healthcare infrastructure, fostering the early adoption of cutting-edge diagnostic tools like BNP and NT-proBNP assays. The prevalence of cardiovascular diseases in North America is notably high, driving the demand for accurate and timely cardiac assessments. The presence of major market players and research institutions dedicated to cardiac health propels innovation. Lastly, strong regulatory frameworks and clinical guidelines support the use of these biomarkers, solidifying North America's dominant position in the BNP and NT-proBNP market.

Key Market Players

Specim, Spectral Imaging Ltd

Gentian Diagnostics ASA

Siemens AG

PerkinElmer Inc

Biomerieux SA

Quidel Corporation

Bio-Rad Laboratories, Inc.

F. Hoffman-La Roche Ltd

BHR Pharmaceuticals Ltd.

Xiamen Biotime Biotechnology Co., Ltd.

Report Scope:

In this report, the Global BNP And NTproBNP Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

BNP And NTproBNP Market, By Type:

    Brain Natriuretic Peptide NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide)

BNP And NTproBNP Market, By Location of Testing:

    Point Of Care Testing Laboratory Testing

BNP And NTproBNP Market, By Application:

    Myocardial Infarction Congestive Heart Failure Acute Coronary Syndrome (ACS) Others

BNP And NTproBNP Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global BNP And NTproBNP Market.

Available Customizations:

Global BNP And NTproBNP Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global BNP And NTproBNP Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type (BNP (Brain Natriuretic Peptide), NT-proBNP (N-terminal Pro-B-Type Natriuretic Peptide))
    • 4.2.2. By Location of Testing (Point Of Care Testing, Laboratory Testing)
    • 4.2.3. By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Type
    • 4.3.2. By Location of Testing
    • 4.3.3. By Application
    • 4.3.4. By Region

5. Asia Pacific BNP And NTproBNP Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Location of Testing
    • 5.2.3. By Application
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China BNP And NTproBNP Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Type
        • 5.3.1.2.2. By Location of Testing
        • 5.3.1.2.3. By Application
    • 5.3.2. India BNP And NTproBNP Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Type
        • 5.3.2.2.2. By Location of Testing
        • 5.3.2.2.3. By Application
    • 5.3.3. Australia BNP And NTproBNP Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Type
        • 5.3.3.2.2. By Location of Testing
        • 5.3.3.2.3. By Application
    • 5.3.4. Japan BNP And NTproBNP Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Type
        • 5.3.4.2.2. By Location of Testing
        • 5.3.4.2.3. By Application
    • 5.3.5. South Korea BNP And NTproBNP Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Type
        • 5.3.5.2.2. By Location of Testing
        • 5.3.5.2.3. By Application

6. Europe BNP And NTproBNP Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Location of Testing
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France BNP And NTproBNP Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Location of Testing
        • 6.3.1.2.3. By Application
    • 6.3.2. Germany BNP And NTproBNP Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Location of Testing
        • 6.3.2.2.3. By Application
    • 6.3.3. Spain BNP And NTproBNP Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Location of Testing
        • 6.3.3.2.3. By Application
    • 6.3.4. Italy BNP And NTproBNP Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Location of Testing
        • 6.3.4.2.3. By Application
    • 6.3.5. United Kingdom BNP And NTproBNP Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Location of Testing
        • 6.3.5.2.3. By Application

7. North America BNP And NTproBNP Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Location of Testing
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States BNP And NTproBNP Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Location of Testing
        • 7.3.1.2.3. By Application
    • 7.3.2. Mexico BNP And NTproBNP Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Location of Testing
        • 7.3.2.2.3. By Application
    • 7.3.3. Canada BNP And NTproBNP Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Location of Testing
        • 7.3.3.2.3. By Application

8. South America BNP And NTproBNP Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Location of Testing
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil BNP And NTproBNP Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Location of Testing
        • 8.3.1.2.3. By Application
    • 8.3.2. Argentina BNP And NTproBNP Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Location of Testing
        • 8.3.2.2.3. By Application
    • 8.3.3. Colombia BNP And NTproBNP Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Location of Testing
        • 8.3.3.2.3. By Application

9. Middle East and Africa BNP And NTproBNP Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Location of Testing
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa BNP And NTproBNP Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Location of Testing
        • 9.3.1.2.3. By Application
    • 9.3.2. Saudi Arabia BNP And NTproBNP Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Location of Testing
        • 9.3.2.2.3. By Application
    • 9.3.3. UAE BNP And NTproBNP Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Location of Testing
        • 9.3.3.2.3. By Application

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global BNP And NTproBNP Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Specim, Spectral Imaging Ltd
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Gentian Diagnostics ASA
  • 14.3. Siemens AG
  • 14.4. PerkinElmer Inc
  • 14.5. Biomerieux SA
  • 14.6. Quidel Corporation
  • 14.7. Bio-Rad Laboratories, Inc.
  • 14.8. F. Hoffman-La Roche Ltd
  • 14.9. BHR Pharmaceuticals Ltd.
  • 14.10. Xiamen Biotime Biotechnology Co., Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제